Standard BioTools Inc. Receivables, Net, Current
Standard BioTools Inc. (LAB) had Receivables, Net, Current of $15.75 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-08-05
- 2026-06-30: Receivables, Net, Current $15.75M.
- 2026-03-31: Receivables, Net, Current $16.64M.
- 2025-12-31: Receivables, Net, Current $13.43M.
- 2025-09-30: Receivables, Net, Current $13.54M.
| Period end | Receivables, Net, Current | Receivables, Net, Current as first filed |
|---|---|---|
| 2026-06-30 | $15.75M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $16.64M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $13.43M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $13.54M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $14.61M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $35.48M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $14.74M 10-K · filed 2026-03-16 | $33.61M 10-K · filed 2025-03-11 |
| 2024-09-30 | $35.32M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $32.44M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $36.01M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $19.66M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |